Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Exclusion Criteria

• •* NOTE: patients can be enrolled up through day 1 of cycle 3 of therapy; the patient is permitted to participate in any other therapeutic therapy for their disease as long as it does not concern vitamin D; patients can begin their chemotherapy while awaiting vitamin D results and treatment arm assignment or
• •* Newly diagnosed untreated peripheral T-cell non-Hodgkin lymphoma (NHL) that will be treated with chemotherapy; NOTE: patients can be enrolled up through day 1 of cycle 3 of therapy; this includes the following disease types:
• •* Peripheral T cell lymphoma, unspecified
• •* Anaplastic large cell lymphoma (T and null cell type)
• •* Extranodal NK/T-cell lymphoma, nasal type
• •* Enteropathy-type T-cell lymphoma
• •* Hepatosplenic T-cell lymphoma
• •* Subcutaneous panniculitis-like T-cell lymphoma
• •* Angioimmunoblastic T-cell lymphoma
• •* Anaplastic large cell lymphoma - primary cutaneous type and
• •* Willing to provide tissue for correlative research purposes
• •Study 2 - CLL/SLL
• •* Newly diagnosed (\< 12 months from pre-registration on this study) CLL according to the National Cancer Institute (NCI) criteria or SLL according to the World Health Organization (WHO) criteria; this includes previous documentation of:
• •* Biopsy-proven small lymphocytic lymphoma
• •* Diagnosis of CLL according to NCI working group criteria as evidenced by all of the following:
• •* Peripheral blood lymphocyte count of \> 5,000/mm\^3; if present, prolymphocytes should be \< 55%
• •* Immunophenotyping consistent with CLL defined as:
• •* The predominant population of lymphocytes share both B-cell antigens (cluster of differentiation \[CD\]19, CD20, or CD23) as well as CD5 in the absence of other pan-T-cell markers (CD3, CD2, etc.)
• •* Dim surface immunoglobulin expression
• •* Restricted surface kappa or lambda light chain expression
• •* Before diagnosing CLL or SLL, mantle cell lymphoma must be excluded by demonstrating a negative fluorescent in situ hybridization (FISH) analysis for t(11;14)(immunoglobulin H \[IgH\]/cyclin D 1 \[CCND1\]) on peripheral blood or tissue biopsy or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy
• •* Rai stage 0 or 1
• •* Previously untreated
• •* Asymptomatic with the plan for observation
• •* Life expectancy of at least 24 months
• •* Willing to provide tissue for correlative research purposes
• •Both Studies:
• •Capable of swallowing intact study medication capsules
• •Serum calcium \< 11 mg/dL; note: patients with hypercalcemia can be enrolled after the calcium is corrected with standard of care treatments
• •Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
• •* Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up
• •Willing to provide blood samples for correlative research purposes
• •Vitamin D level (25 hydroxy D2 + hydroxyl D3) confirmed by central laboratory review
• •Patients with Burkitt lymphoma or any patient receiving rituximab-cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate / ifosfamide, etoposide, high-dose cytarabine (R- CODOXM/IVAC)
• •Patients who previously had indolent lymphoma and now at a separate episode have large cell NHL (i.e. transformation